ALLOGENE THERAPEUTICS INC (ALLO)
Health Care · Allogeneic CAR-T cell immunotherapy · NASDAQ
Allogene Therapeutics is pioneering off-the-shelf, donor-derived CAR T cell therapies to provide more scalable and accessible cancer and autoimmune disease treatments.
What ALLOGENE THERAPEUTICS INC does
Allogene Therapeutics is a clinical-stage immuno-oncology company pioneering genetically engineered allogeneic (donor-derived) T cell product candidates for cancer and autoimmune diseases. Unlike autologous therapies that use a patient's own cells, Allogene's approach uses healthy donor T cells engineered to be "off-the-shelf" products available to any patient, aiming to deliver treatments faster, more reliably, and at greater scale. The company uses gene-editing technologies (TALEN and CRISPR) to minimize graft-versus-host disease risk and employs its proprietary Dagger® technology to enhance CAR-T cell expansion and persistence.
Themes: Allogeneic CAR-T immunotherapy, Large B-cell lymphoma (LBCL), Renal cell carcinoma (RCC), Autoimmune disease treatment, Gene-edited cell therapy, Off-the-shelf oncology
Fundamentals
- Price$2.09 as of 2026-08-21 close
- Market cap$722M as of 2026-08-21
- 1-year return+86.6% 2025-08-21 close $1.12 → 2026-08-21 close $2.09
- P/En/a negative earnings
- Net margin-269835.0% as of 2026-08-24
- ROE-57.1% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta0.54 as of 2026-08-24
- Last reported earnings2026-08-12 SEC EDGAR Form 8-K (Item 2.02)
How ALLO compares in its sector
- net profit marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ALLOGENE THERAPEUTICS INC looks technically
ALLOGENE THERAPEUTICS INC (ALLO) is trading 9.2% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 162 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 3 trading days ago. It is 53.1% below its highest point of the past year.
Trend
9
| Distance from the 200-day | it is trading 9.2% above its 200-day average, the long-term trend line — a longer-term uptrend | +9.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $1.98 | $1.98 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $1.91 | $1.91 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 1.92. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 162 trading days ago — a "golden cross", a bullish long-term signal | 162 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 9.2% above | +9.2% |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend) | 15.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30) | 54.7 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($1.82 to $2.23) — its "stochastic" reading is 66 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 65.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 17 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $4.46 | $4.46 |
|---|---|---|
| From the 52-week high | it is 53.1% below its 52-week high (its highest price of the past year) | -53.1% |
| Above the 52-week low | it is 102.9% above its 52-week low (its lowest price of the past year) | +102.9% |
| Below the 52-week high | it is 53.1% below its highest point of the past year | 53.1% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day low about 19 trading days ago | 19 sessions |
| All-time high | its highest closing price on record is $55.00 (set on 2020-05-26) | $55.00 |
| Given back of the 52-week move | over the past year its closes ranged ($1.05 to $3.06), and it has given back around half of its rise from last year’s low — 48% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $1.75 to $1.82. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 48.3% |
| From the all-time high | it is 96.2% below its all-time high | -96.2% |
| Nearest price level | it is trading 1.1% above a support level at $2.07 — a price it turned at twice since 2026-03-20, most recently on 2026-05-01. Since 2024-08-21 it has 7 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.1% |
| All-time low | its lowest closing price on record is $0.8621 (set on 2025-05-14) | $0.8621 |
| Above the all-time low | it is 142.4% above its all-time low | +142.4% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 45th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1256 between its high and its low — about 6.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1256 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $1.71 and $2.25 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $1.71 – $1.98 – $2.25 |
| Typical daily range (% of price) | its price moves about 6.0% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.0% |
| Stretch from the 200-day average | it is trading 1.4 daily ranges above its 200-day average price (9.2% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.74× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 8 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 8 sessions ago |
|---|---|---|
| Since a bearish engulfing | 7 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 7 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.0% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.9% |
|---|---|---|
| Open gap | it gapped 2.5% above the previous close 2 sessions ago and has not traded back through the level it left behind at 2.03 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.5% |
| Gap filled | a 2.9% gap up opened on 2026-08-13 has been "filled" 6 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 6 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -6.28% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 10.6 percentage points (the stock gained 13.0% while the market gained 2.3%) | +10.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 3.5 percentage points (the stock gained 6.6% while the market gained 3.1%) | +3.5% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 9.1 percentage points (the stock gained 2.0% while the market gained 11.1%) | -9.1% |
| vs market, 12 months | over the past 12 months this stock beat the market by 66.1 percentage points (the stock gained 86.6% while the market gained 20.5%) | +66.1% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: lagging the market over 6 months — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 1.0% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 4.1% of the share price. | +1.0% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 3% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $2.15 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | -3.0% |
|---|
Price levels it has turned at before
ALLO last closed at $2.09 on 2026-08-21. Since 2024-08-21 it has turned at 7 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $2.07 | Support | 1.1% below the last close | turned there twice · 2026-03-20 to 2026-05-01 |
| $2.19 | Resistance | 5.0% above the last close | turned there twice · 2026-03-06 to 2026-08-11 |
| $1.98 | Support | 5.3% below the last close | turned there twice · 2024-11-20 to 2026-02-03 |
| $2.32 | Resistance | 11.0% above the last close | turned there twice · 2025-03-07 to 2026-05-27 |
| $1.84 | Support | 11.7% below the last close | turned there twice · 2026-04-15 to 2026-05-21 |
| $2.39 | Resistance | 14.5% above the last close | turned there four times · 2024-09-06 to 2026-05-11 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $1.92.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 1 trading day, since 2026-08-21.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Pulled back from the 12-month high · Broke out to a new 20-day high · trendless / choppy (low ADX) · lagging the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.42 mean, 1=Strong Buy…5=Strong Sell) — 9 analysts
- Mean price target$9.00 range $4.00 – $14.00
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ALLO
- Consensus EPS estimate-$0.1407 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical development risk: Company is clinical-stage with no approved products; multiple anticipated readouts in Q2 2026 are critical to validate key scientific assumptions about off-the-shelf CAR-T safety and efficacy.","Manufacturing and scalability risk: Success depends on building and maintaining state-of-the-art cGMP manufacturing capabilities; a death attributed to disseminated adenovirus infection in the FCA arm of ALPHA3 has already prompted changes to the trial protocol.","Allogeneic rejection risk: Allogeneic T cell therapies face inherent biological challenges including graft-versus-host disease and host-mediated rejection, which the company attempts to address through gene editing and Dagger® technology but remain unproven at commercial scale."]
What changed in the latest 10-Q
AI-assisted comparison of ALLO's 10-Q filed 2026-05-13 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to Annual Report filed on March 12, 2026 (newer filing dated 2026-05-13)
- Statement that global expansion is expected to bring ALPHA3 trial to more than 80 sites worldwide
- Note that Foresight Diagnostics was acquired by Natera, Inc. in December 2025 and continues to operate as a standalone subsidiary
- Announcement on April 13, 2026 of results from planned interim futility analysis of first 24 randomized patients
- Specific MRD negativity rates: 58.3% (7/12) in cema-cel arm vs 16.7% (2/12) in observation arm
- ctDNA median decrease of 97.7% in cema-cel arm compared with median increase of 26.6% in observation arm
- Statement that no treatment-related serious adverse events, cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, graft-versus-host disease or treatment-related hospitalizations were reported in cema-cel arm
- Removed:
- Reference to Annual Report filed on March 13, 2025 (older filing dated 2025-11-06)
- Statement about 'Last year we announced our 2024 Platform Vision'
- Reference to trial-in-progress poster presented at 2025 ASCO Annual Meeting
- Statement that 'We now have over 50 activated trial sites in the United States and Canada'
- Information about Additional sites in Australia and South Korea expected to open in early 2026
- References to meetings with EU regulatory authorities and scientific advice received
- Information about operational feasibility assessments for EU and UK
- Statement that 'The amended ALPHA3 trial now proceeds as a randomized study'
- Statement about futility analysis 'expected to occur in the first half of 2026'
- Statement about providing MRD conversion rates at announcement time
- Statement about not providing guidance regarding timing of additional milestones beyond futility analysis
- Reworded:
- Changed 'risk of relapse due to minimal residual disease (MRD)' to 'remain at risk of relapse due to minimal residual disease (MRD)'
- Changed 'The amended ALPHA3 trial now proceeds' to 'The amended ALPHA3 trial is proceeding'
- Changed 'approximately 240' to 'approximately 220' for expected enrollment (amendment related to two-arm design)
- Changed description from 'now proceeds as a randomized study with two arms' to 'is proceeding as a randomized study with two arms, comparing cema-cel after standard FC lymphodepletion to observation' with additional detail on expected enrollment of approximately 220 patients
- Notes:
- Newer filing text appears truncated at end of provided excerpt ('ten of the twelve treated pati'); full comparison of remaining content not possible
- Comparison reflects only the portion of MD&A provided; full document may contain additional changes not visible in excerpts
Risk Factors
- Added:
- Added risk factor (filed 2026-05-13): 'Disruptions to the operations of the FDA, the SEC and other government agencies, including comparable foreign regulatory authorities, resulting from funding shortages, policy initiatives, staffing reductions or related uncertainty, could impair their ability to perform regulatory functions and negatively impact our business.'
- Removed:
- Removed risk factor (filed 2025-11-06): 'Increased interest among investors and large pharmaceutical companies in in vivo cell-engineering technologies may adversely affect our ability to raise capital or secure development partnerships.'
- Removed longer version of FDA/regulatory disruption risk (filed 2025-11-06): 'Disruptions to the operations of the FDA, the SEC and other government agencies, including comparable foreign regulatory authorities, including those caused by funding shortages, in addition to substantial uncertainty regarding the current administration's initiatives and staffing cuts and how these might impact the FDA, the SEC and other governmental agencies implementation of laws, regulations, policies and guidance, and its personnel, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.'
- Reworded:
- Risk factor wording simplified (filed 2026-05-13 vs 2025-11-06): FDA/regulatory disruption risk was condensed from reference to 'current administration's initiatives and staffing cuts' and 'substantial uncertainty' language to more neutral 'policy initiatives' and 'related uncertainty' phrasing
- Risk factor wording changed (filed 2026-05-13): 'Foresight Diagnostics' now identified as 'a subsidiary of Natera' (added corporate parent designation)
- Notes:
- Newer filing text is truncated at 'Risks Related to Our Fina' so full Risk Factors section is not available for complete comparison
- Comparison is limited to the Risk Factor Summary and opening portion of the full Risk Factors section that are both present in truncated text
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days0 buys · 4 sells ($159228) — 3 selling insiders
Most recent open-market transaction: 2026-04-21. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ALLO's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding ALLO as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 38,367,679
- Reported value $93,617,138
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
ALLO had 60,753,788 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
ALLO had 17.6% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9.23 days to cover at the same settlement.
- Reported short interest (shares) 60,753,788
- Short interest (% of shares outstanding) 17.6%
- Prior settlement (shares) 59,712,398
- Reported change 1.74%
- Days to cover (reported) 9.23
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Gilead Sciences (Kite) (GILD)
- Novartis (NVS)
- Bristol-Myers Squibb (BMY)
- Johnson & Johnson (JNJ)
- Legend Biotech (LEGN)
- Autolus Therapeutics (AUTL)
- Caribou Biosciences (CRBU)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ALLO vs…
Frequently asked questions
What does ALLOGENE THERAPEUTICS INC (ALLO) do?
Allogene Therapeutics is a clinical-stage immuno-oncology company pioneering genetically engineered allogeneic (donor-derived) T cell product candidates for cancer and autoimmune diseases. Unlike autologous therapies that use a patient's own cells, Allogene's approach uses healthy donor T cells engineered to be "off-the-shelf" products available to any patient, aiming to deliver treatments faster, more reliably, and at greater scale.
What sector is ALLOGENE THERAPEUTICS INC (ALLO) in?
ALLOGENE THERAPEUTICS INC (ALLO) is classified in the Health Care sector. Its industry is Allogeneic CAR-T cell immunotherapy. It trades on NASDAQ.
Who are ALLOGENE THERAPEUTICS INC's (ALLO) competitors?
Notable peers of ALLOGENE THERAPEUTICS INC (ALLO) include Gilead Sciences (Kite), Novartis, Bristol-Myers Squibb, Johnson & Johnson and Legend Biotech. This peer set is informational only — not financial advice.
Is ALLOGENE THERAPEUTICS INC (ALLO) overbought or oversold right now?
ALLOGENE THERAPEUTICS INC (ALLO) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 55, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ALLO come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.